

#5/R.T.
5/8

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Cindy Hoang		
Signature	Cindy Hoang	Date	4/23/02

O I P AMENDMENT UNDER
37 C.F.R. §1.111

MAY 02 2002

PATENT & TRADEMARK OFFICE

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket Confirmation No.	UCSF085CON2 4958
First Named Inventor	NADEL
Application Number	09/865,239
Filing Date	May 24, 2001
Group Art Unit	1635
Examiner Name	J. Zara
Title	PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS

RECEIVED
MAY 06 2002
TECH CENTER 1600/290

Sir:

This amendment is responsive to the Office Action dated January 28, 2002, for which a three-month period for response was given making this response due on or before April 28, 2002. Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

I. AMENDMENTS

*Allowed
claims*

IN THE CLAIMS

Please enter the amendments to claims 28, 34, and 40, as shown below.

B¹ 1. 28. (Amended) A pharmaceutical formulation for treatment of airway mucus hypersecretion,

comprising:

a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist that binds to an EGF-R, wherein said amount is effective to reduce airway mucus hypersecretion; and a flowable formulation suitable for delivery by inhalation.

B² 2. 34. (Amended) A package for use in treating airway mucus hypersecretion, comprising a

container having therein a flowable formulation comprising a pharmaceutically active epidermal growth factor receptor (EGF-R) antagonist that binds to an EGF-R, wherein the EGF-R antagonist is present in the formulation in an amount effective to reduce airway mucus hypersecretion.